Insights & news

Dutch Competition Authority Accepts Roche Commitments Regarding Supply of Testing Materials for SARS-CoV-2 Test

  • 06/04/2020
  • Articles

Autoriteit Consument en Markt, the Dutch competition authority (“ACM”), published on 3 April 2020 a press release expressing satisfaction with commitments made by Roche Diagnostics (“Roche”) regarding the supply of testing materials for the SARS-CoV-2 test (see, attachments). Roche, which ACM says has a “key position” for testing equipment and materials in The Netherlands, had been accused of withholding such materials, including lysis buffer solution, a reagent used to break open cells. On 26 March 2020, the Dutch second Parliamentary Chamber even voted a resolution which observed a shortage of that solution, attributed blame for the alleged shortage to Roche, and called on the government to compel Roche to share the recipe, if necessary by relying on a compulsory patent licence.
 
Roche rejected the allegations and pointed out that it had not even claimed patent protection for the recipe. According to Roche, which pointed out that it developed the first SARS-CoV-2 test in record time, the issue had arisen because Roche could not guarantee the safety and reliability of test results if the reagents were produced in facilities not under its control.
 
For its part, ACM made it clear that Roche had exhibited a “constructive attitude” by sharing the recipe for lysis buffer solution and helping in expanding production. This is why ACM did not consider further action necessary. In passing, ACM pointed out that it had worked closely with the European Commission as many Member States are grappling with similar problems. 

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more
    • 29/05/2020
    • Articles

    European Commission Presents EU4Health Programme

    On 28 May 2020 the European Commission (the Commission) presented details of its new, stand-alone EU4Health Programme, a proposal to commit considerable EU resources to health during the 2021-2027 period (EU4Health). The budget which the Commission proposes to earmark for EU4Health, EUR 9.4 billion, reflects a more than 20-fold increase over the funds previously dedicated to this policy area (EUR 413 million). The Commission first made its plan public as part of the presentation of ‘Next Generation EU’, a EURO 750 billion recovery plan to be embedded in and added to the long term overall EU budget for the 2021-2027 period (see, Van Bael & Bellis Life Sciences News Alert, 28 May 2020).

    Read more
    • 28/05/2020
    • Articles

    Next Generation EU - European Commission Proposes Significant Funding and Expanded EU Health Programme

    The European Commission (the Commission) published on 27 May 2020 its proposal for a major recovery plan and put forward a new EUR 750 billion recovery instrument called ‘Next Generation EU’ that would be embedded in and added to the long term EU budget (itself worth some EUR 1,100 billion between 2021 and 2027). The money from Next Generation EU would be available to the Member States in the form of both grants (EUR 500 billion) and loans (EUR 250 billion). The focus of the recovery plan is the green and digital transition but the plan also has a substantial health component, at times intertwined with green and digital aspects.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *